Skip to main content
Clinical Trials/NCT03019133
NCT03019133
Completed
Not Applicable

Prospective Randomized Controlled Trial to Compare and Analyze the Effects of Sound Masking and Reduction Techniques on Heart Rate and Blood Pressure Variability in Critically Ill Patients

Brian Gehlbach1 site in 1 country120 target enrollmentDecember 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Critical Illness
Sponsor
Brian Gehlbach
Enrollment
120
Locations
1
Primary Endpoint
Nocturnal LF/HF ratio (a.u.)
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of the project is to determine the effects of noise masking and noise reduction on stress related physiological parameters in critically ill patients admitted to the intensive care unit.

Detailed Description

Sleep deprivation is common in critically ill patients in the intensive care unit (ICU) and may impair recovery. While noise is widely cited as the most common cause of sleep disruption in the ICU setting, its contribution to sympathetic activity in critically ill patients is not known. This is an important knowledge gap, because noise initiates a sequence of physiological changes including vasoconstriction, raised diastolic blood pressure, pupil dilatation and muscle tension. Furthermore, noise is implicated in sympathetic arousals, resulting in a release of adrenaline which prevents relaxation and consequently prevents the patient from falling asleep. The investigators plan to study the effect of noise masking and noise reduction on stress related physiological parameters in critically ill patients admitted to the ICU. Subjects will be randomized into 3 separate groups: control, noise reduction, and noise masking. The investigators will compare the heart rate and blood pressure variability between and within the groups to determine the effects of treatment assignment on these variables. Non-invasive measurements obtained from the bedside monitor will be collected using physiological data acquisition software.

Registry
clinicaltrials.gov
Start Date
December 2016
End Date
December 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Brian Gehlbach
Responsible Party
Sponsor Investigator
Principal Investigator

Brian Gehlbach

Clinical Associate Professor

University of Iowa

Eligibility Criteria

Inclusion Criteria

  • Subjects aged 18-99 years who are expected to receive care on an adult critical care unit for at least 24 hours

Exclusion Criteria

  • Admission for drug overdose or with a known substance abuse disorder
  • Untreated sleep apnea disorder, narcolepsy, REM sleep behavior disorder, parasomnia, restless leg syndrome or other sleep disorder
  • Use of hearing aids, or known significant conductive or sensory hearing loss
  • Ventilator support via an endotracheal tube
  • Use of vasopressors
  • Unresponsive or delirious
  • Subjects with known Dementia, Parkinson's disease, or other neurodegenerative disorder
  • Subjects with a pacemaker or who have received cardiac transplant

Outcomes

Primary Outcomes

Nocturnal LF/HF ratio (a.u.)

Time Frame: Day 1 of study

The effect of group assignment on nocturnal (8pm to 8am) low frequency/high frequency (LF/HF) ratio will be determined.

Secondary Outcomes

  • Hospital mortality (%)(Assessed at the time of hospital discharge up to a maximum of 28 days after enrollment, and averaging 6 days after enrollment.)
  • Incidence of ICU delirium(Assessed at the time of ICU discharge up to a maximum of 28 days after enrollment, and averaging 4 days after enrollment)
  • Nocturnal heart rate (bpm)(Day 1 of study)
  • Nocturnal RMSSD (ms)(Day 1 of study)
  • Nocturnal blood pressure (mm Hg)(Day 1 of study)
  • Hospital length of stay (days)(Assessed at the time of hospital discharge up to a maximum of 28 days after enrollment, and averaging 6 days after enrollment.)
  • Discharged home (%, versus discharge to another health care facility or died)(Assessed at the time of hospital discharge up to a maximum of 28 days after enrollment, and averaging 6 days after enrollment.)
  • ICU length of stay (days)(Assessed at the time of ICU discharge up to a maximum of 28 days after enrollment, and averaging 4 days after enrollment.)

Study Sites (1)

Loading locations...

Similar Trials